Atlas Trials

Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

Clinical trial NCT03129828 · COMPLETED

Trial details

NCT number
NCT03129828
Sponsor
Prof. Dr. Clemens Schmitt
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma
Start date
2017-03-17
Primary completion
2024-11-12
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.